Alloy Therapeutics announced it has raised $40 million in a Series E round, reaching a $1 billion valuation as it expands its AI-powered platform for drug discovery and development. The round included new investors such as 8VC, JIC Venture Growth Investments, and Echo Capital, alongside existing backers including Mubadala Capital, Presight Capital, Thiel Capital, Founders Fund, Alexandria Venture Investments, Gaingels, and Ulysses Diversified Holdings.
Founded in 2017, Alloy has evolved from an antibody discovery platform into a full-stack biotech infrastructure company, supporting more than 200 partners and over 100 licensed therapeutic programs. Of these, 22 have advanced to clinical development, including two drugs currently in Phase 3 trials.
Alloy’s platform integrates artificial intelligence, real-world data, and wet lab capabilities to streamline the drug development lifecycle, from discovery through preclinical and clinical stages to manufacturing. The company’s model is designed to enable virtual biotechs and lean development teams to access advanced infrastructure without building it internally.
The new funding will support expansion across three core areas: strengthening discovery services in antibodies, genetic medicines, and cell therapies; scaling downstream preclinical and clinical development capabilities; and advancing the company’s AI and data infrastructure.
Alloy is positioning itself as a central infrastructure layer for the biopharma industry, enabling more capital-efficient development of therapeutics through a combination of proprietary technology and service-based collaboration.
The company continues to expand its global footprint, with centers of excellence across the United States, Japan, the Middle East, and other emerging innovation hubs, supporting a decentralized approach to drug development.
KEY QUOTES:
“Alloy is building the infrastructure layer connecting discovery, development, and data across the global biopharma industry. We are bridging the enormous strengths of traditional BioPharma and cutting-edge TechBio to reimagine what’s possible for making new medicine. Technological innovation, including AI at every step of the process, is driving a rapid evolution that no single pharma company can keep up with. Alloy’s collaborative, service-oriented model allows our partners to stay at the cutting edge without having to innovate in every dimension or hire the people and infrastructure they may only need intermittently.”
Errik Anderson, Founder And CEO, Alloy Therapeutics
“We’ve watched Errik build Alloy methodically for nearly a decade into a company that has quietly redefined what drug development can look like at scale. While all industries are being disrupted by AI in front of our eyes, Alloy understands that real disruption in biopharma is coming from integrating AI as part of an ‘x-in-the-loop’ strategy with real-world capabilities.”
Alex Kolicich, 8VC
“Strengthening Japan’s position in global life sciences requires investing in the infrastructure that enables innovation to move faster, more efficiently, and without borders. Alloy’s model – connecting world-class proprietary technologies and services across geographies, including its growing presence in Japan – not only enhances Japan’s integration into the global innovation ecosystem, but also supports the development of globally competitive talent, reflecting exactly the kind of global ecosystem we seek to support.”
Hanae Suzuki, JIC Venture Growth Investments
